EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Convection-enhanced delivery of dexamethasone in glioma models suppresses myeloid inflammation while avoiding systemic toxicities

Nathaniel W Rolfe, Nicholas B Dadario, Liang Lei, Anthony J Tang, Misha Amini, Damian E Teasley, Nkechime Ifediora, Peter J Chabot, Nathan J Winans, Nina Yoh, Julia Furnari, Corina Kotidis und 16 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci200550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Nathaniel W Rolfe und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery. Hauptthemen laut MEDLINE: Dexamethasone, Glioma, Brain Neoplasms, Myeloid Cells. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dexamethasone is widely used to control cerebral edema and inflammation in glioblastoma, but its benefits are limited by systemic toxicities and adverse prognostic associations. We evaluated local administration of dexamethasone via convection-enhanced delivery (CED) to maximize intratumoral antiinflammatory effects by increasing local corticosteroid exposure while minimizing systemic exposure. In 2 glioma mouse models, continuous intraparenchymal infusion of dexamethasone was well tolerated with no adverse effects. Pharmacokinetic analyses supported preferential intratumoral distribution and reduced systemic exposure with CED compared with systemic dosing. Single-nucleus RNA sequencing and immunohistochemistry showed attenuation of glioma-associated inflammation with downregulation of reactive microglial/macrophage programs and reduced tumor-infiltrating myeloid cells with a morphology consistent with a less activated state. Experiments in human induced pluripotent stem cell–derived microglia confirmed that dexamethasone directly suppresses inflammatory gene expression, indicating a conserved mechanism across species. This inflammatory suppression was recapitulated in both immortalized microglial (HMC3) and macrophage (THP-1) cell lines. These findings suggest that localized dexamethasone delivered by CED reprograms the glioma immune microenvironment and achieves control of inflammation without the systemic adverse effects associated with standard systemic dexamethasone therapy. This clinically translatable strategy may improve symptom management and provide a platform for integrating local immunomodulation with future glioblastoma therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneGliomaBrain NeoplasmsMyeloid CellsDrug Delivery SystemsAnimalsHumansMiceInflammationConvectionMicrogliaMacrophagesFemaleCell Line, Tumor

Stichwörter der Autor:innen

Brain cancerInflammationMacrophagesOncology

Substanzen

Dexamethasone

Autor:innen und Institutionen

  • Department of Neurological Surgery.
  • Department of Pathology and Cell Biology.
  • Insititue of Comparative Medicine (ICM), and.
  • Oncology Precision Therapeutics and Imaging Core (OPTIC), Columbia University Irving Medical Center and NY-Presbyterian Hospital, New York, New York, USA.
  • Department of Biostatistics and.
  • Department of Systems Biology, Columbia University Irving Medical Center, New York, New York, USA.

Förderung

  • NINDS NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • NIH

Zitieren

APA

Rolfe, N. W., Dadario, N. B., Lei, L., Tang, A. J., Amini, M., Teasley, D. E., Ifediora, N., Chabot, P. J., Winans, N. J., Yoh, N., Furnari, J., Kotidis, C., Stucke, C. H., Urena, N. M., Sun, Y., Brand, A. L., Viswanathan, A., Upadhyayula, P., Argenziano, M. G., …, & Bruce, J. N. (2026). Convection-enhanced delivery of dexamethasone in glioma models suppresses myeloid inflammation while avoiding systemic toxicities. Journal of Clinical Investigation. https://doi.org/10.1172/jci200550

Vancouver

Rolfe NW, Dadario NB, Lei L, Tang AJ, Amini M, Teasley DE, et al. Convection-enhanced delivery of dexamethasone in glioma models suppresses myeloid inflammation while avoiding systemic toxicities. Journal of Clinical Investigation. 2026. doi:10.1172/jci200550

BibTeX
@article{Rolfe2026,
  author = {Rolfe, Nathaniel W and Dadario, Nicholas B and Lei, Liang and Tang, Anthony J and Amini, Misha and Teasley, Damian E and Ifediora, Nkechime and Chabot, Peter J and Winans, Nathan J and Yoh, Nina and Furnari, Julia and Kotidis, Corina and Stucke, Clara H and Urena, Nivia M and Sun, Yanping and Brand, Abby L and Viswanathan, Ashwin and Upadhyayula, Pavan and Argenziano, Michael G and Sperring, Colin P and Khoury, Nadine and Humala, Nelson and Wang, Shikun and Neira, Justin and Sims, Peter A and Gill, Brian Ja and Canoll, Peter and Bruce, Jeffrey N},
  title = {Convection-enhanced delivery of dexamethasone in glioma models suppresses myeloid inflammation while avoiding systemic toxicities},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci200550}
}
Kostenlos starten →